- A gross income of $250,000 or more per annum in each of the previous two financial years; or
- Net assets of at least $2.5 million; and
- A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
Live Investor Briefing
Prescient Therapeutics (ASX: PTX)
Friday, 5th April 12pm (AEDT)
Join Prescient CEO and Managing Director Steven Yatomi-Clarke for a special investor briefing on targeted cell therapy PTX-100.
Steven will discuss:
- The new PTX-100 Phase 1b clinical study results, following their unveiling at the American Society of Hematology (ASH) conference.
- The next steps for PTX-100 including preparation for a meeting with the FDA to discuss using the Phase 2 trial as a registrational study.
- The potential significance of accelerating approval and commercialisation of PTX-100 in an orphan disease.
This is a live and interactive online session, and participants are encouraged to ask questions. Spots are limited, so secure yours today.
Can’t make this time, register to receive the replay.
Attend the session
What is a 708 investor?By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Corporate provides Corporate Advisory Services to Prescient Therapeutics Limited and has been engaged by them to manage their investor communications including managing this offer and may receive fees for its services.
Featured Speaker
Steven Yatomi-Clarke
CEO and Managing Director
Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.
Dr Rebecca Lim
Senior Vice President of Scientific Affairs
Dr Rebecca Lim has over 10 years of experience in allogeneic cell therapies for regenerative medicine. She was previously the Scientific Director for the Cell Therapies Platform at the Hudson Institute and an Associate Professor at Monash University.